ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

HHLA2 Vs PD-L1 Expression in Urothelial Tumors

Alexander I. Sankin, MD
Published Online:7:23 PM, Thu September 1, 2016

Alexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.